Skip to main content
Top
Published in: European Journal of Medical Research 1/2016

Open Access 01-12-2016 | Research

The value of initial cavitation to predict re-treatment with pulmonary tuberculosis

Authors: Qiusheng Huang, Yongmei Yin, Shougang Kuai, Yan Yan, Jun Liu, YingYing Zhang, Zhongbao Shan, Lan Gu, Hao Pei, Jun Wang

Published in: European Journal of Medical Research | Issue 1/2016

Login to get access

Abstract

Objective

Pulmonary cavitation is the classic hallmark of pulmonary tuberculosis (PTB) and is the site of very high mycobacterial burden associated with antimycobacterial drug resistance and treatment failure. The objective of this study was to investigate the relationship between re-treatment PTB and initial pulmonary cavitation coordinated with other clinical factors.

Methods

We conducted a case–control study of 291 newly diagnosed cases of pulmonary TB in The Infectious Hospital of Wuxi from Dec 2009 to Dec 2011 with complete follow-up information until December 31st of 2014. 68 patients were followed-up with PTB re-treatment; the rest of the PTB patients (n = 223) had completed anti-TB treatment, and cured without re-treatment were selected as controls.

Results

The univariate analysis [hazard ratio (HR) 1.885, 95 % CI 1.170–3.035, P = 0.009] and the multivariable analysis (HR 2.242, 95 % CI 1.294–3.882, P = 0.004) demonstrated that the initial pulmonary cavitation was a prognostic predictor for TB re-treatment. Additionally, the re-treatment rates in PTB patients with cavitation and no-cavitation were 27.1 and 15.5 %, respectively, with significant difference (log-rank test; P = 0.010). Other factors, age of ≥60 and history of smoking, were also prognostic variables.

Conclusion

Initial pulmonary cavitation of chest X-ray was a significant predictor for PTB re-treatment
Literature
1.
go back to reference World Health Organization. Global tuberculosis report 2014. Geneva: World Health Organization; 2014. World Health Organization. Global tuberculosis report 2014. Geneva: World Health Organization; 2014.
2.
go back to reference Hill AN, Becerra J, Castro KG. Modelling tuberculosis trends in the USA. Epidemiol Infect. 2012;140(10):1862–72.CrossRefPubMed Hill AN, Becerra J, Castro KG. Modelling tuberculosis trends in the USA. Epidemiol Infect. 2012;140(10):1862–72.CrossRefPubMed
3.
go back to reference Surveillance report: tuberculosis surveillance and monitoring in Europe 2013. Geneva: World Health Organization; 2013. Surveillance report: tuberculosis surveillance and monitoring in Europe 2013. Geneva: World Health Organization; 2013.
4.
go back to reference Public Health England. Tuberculosis in the UK 2013 report. London: Public Health England; 2013. Public Health England. Tuberculosis in the UK 2013 report. London: Public Health England; 2013.
5.
go back to reference Crofts JP, Andrews NJ, Barker RD, Delpech V, Abubakar I. Risk factors for recurrent tuberculosis in England and Wales, 1998–2005. Thorax. 2010;65(4):310–4.CrossRefPubMed Crofts JP, Andrews NJ, Barker RD, Delpech V, Abubakar I. Risk factors for recurrent tuberculosis in England and Wales, 1998–2005. Thorax. 2010;65(4):310–4.CrossRefPubMed
6.
go back to reference World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Geneva: World Health Organization; 2010. World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Geneva: World Health Organization; 2010.
7.
go back to reference Murray J, Sonnenberg P, Shearer SC, Godfrey-Faussett P. Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients. Am J Respir Crit Care Med. 1999;159(3):733–40.CrossRefPubMed Murray J, Sonnenberg P, Shearer SC, Godfrey-Faussett P. Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients. Am J Respir Crit Care Med. 1999;159(3):733–40.CrossRefPubMed
8.
go back to reference Wang L, Zhang H, Ruan Y, Chin DP, Xia Y, Cheng S, et al. Tuberculosis prevalence in China, 1990–2010; a longitudinal analysis of national survey data. Lancet. 2014;383(9934):2057–64.CrossRefPubMed Wang L, Zhang H, Ruan Y, Chin DP, Xia Y, Cheng S, et al. Tuberculosis prevalence in China, 1990–2010; a longitudinal analysis of national survey data. Lancet. 2014;383(9934):2057–64.CrossRefPubMed
9.
go back to reference Kempker RR, Rabin AS, Nikolaishvili K, Kalandadze I, Gogishvili S, Blumberg HM, Vashakidze S. Additional drug resistance in Mycobacterium tuberculosis isolates from resected cavities among patients with multidrug-resistant or extensively drug-resistant pulmonary tuberculosis. Clin Infect Dis. 2012;54(6):e51–4.CrossRefPubMedPubMedCentral Kempker RR, Rabin AS, Nikolaishvili K, Kalandadze I, Gogishvili S, Blumberg HM, Vashakidze S. Additional drug resistance in Mycobacterium tuberculosis isolates from resected cavities among patients with multidrug-resistant or extensively drug-resistant pulmonary tuberculosis. Clin Infect Dis. 2012;54(6):e51–4.CrossRefPubMedPubMedCentral
10.
go back to reference Chatterjee A, D’Souza D, Vira T, Bamne A, Ambe GT, Nicol MP, Wilkinson RJ, Mistry N. Strains of mycobacterium tuberculosis from western Maharashtra, India, exhibit a high degree of diversity and strain-specific associations with drug resistance, cavitary disease, and treatment failure. J Clin Microbiol. 2010;48(10):3593–9.CrossRefPubMedPubMedCentral Chatterjee A, D’Souza D, Vira T, Bamne A, Ambe GT, Nicol MP, Wilkinson RJ, Mistry N. Strains of mycobacterium tuberculosis from western Maharashtra, India, exhibit a high degree of diversity and strain-specific associations with drug resistance, cavitary disease, and treatment failure. J Clin Microbiol. 2010;48(10):3593–9.CrossRefPubMedPubMedCentral
11.
go back to reference Benator D, Bhattacharya M, Bozeman L, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet. 2002;360(9332):528–34.CrossRefPubMed Benator D, Bhattacharya M, Bozeman L, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet. 2002;360(9332):528–34.CrossRefPubMed
12.
go back to reference Baussano I, Pivetta E, Vizzini L, Abbona F, Bugiani M. Predicting tuberculosis treatment outcome in a low-incidence area. Int J Tuberc Lung Dis. 2008;12(12):1441–8.PubMed Baussano I, Pivetta E, Vizzini L, Abbona F, Bugiani M. Predicting tuberculosis treatment outcome in a low-incidence area. Int J Tuberc Lung Dis. 2008;12(12):1441–8.PubMed
13.
go back to reference East African/British Medical Research Councils. Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. Second report of the 4th study. Am Rev Respir Dis. 1981;123(2):165–70. East African/British Medical Research Councils. Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. Second report of the 4th study. Am Rev Respir Dis. 1981;123(2):165–70.
14.
go back to reference Zierski M, Bek E, Long MW, Jr Snider D E. Short-course (6 month) cooperative tuberculosis study in Poland: results 18 months after completion of treatment. Am Rev Respir Dis. 1981;124(3):249–51.PubMed Zierski M, Bek E, Long MW, Jr Snider D E. Short-course (6 month) cooperative tuberculosis study in Poland: results 18 months after completion of treatment. Am Rev Respir Dis. 1981;124(3):249–51.PubMed
15.
16.
go back to reference Kaplan G, Post FA, Moreira AL, Wainwright H, Kreiswirth BN, Tanverdi M, et al. Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect Immun. 2003;71(12):7099–108.CrossRefPubMedPubMedCentral Kaplan G, Post FA, Moreira AL, Wainwright H, Kreiswirth BN, Tanverdi M, et al. Mycobacterium tuberculosis growth at the cavity surface: a microenvironment with failed immunity. Infect Immun. 2003;71(12):7099–108.CrossRefPubMedPubMedCentral
17.
go back to reference Barry S, Breen R, Lipman M, Johnson M, Janossy G. Impaired antigen-specific CD4 + T lymphocyte responses in cavitary tuberculosis. Tuberculosis. 2009;89(1):48–53.CrossRefPubMed Barry S, Breen R, Lipman M, Johnson M, Janossy G. Impaired antigen-specific CD4 + T lymphocyte responses in cavitary tuberculosis. Tuberculosis. 2009;89(1):48–53.CrossRefPubMed
18.
go back to reference Bam TS, Gunneberg C, Chamroonsawasdi K, Bam DS, Aalberg O. Factors affecting patient adherence to DOTS in urban Kathmandu. Nepal. Int J Tuberc Lung Dis. 2006;10(3):270–6.PubMed Bam TS, Gunneberg C, Chamroonsawasdi K, Bam DS, Aalberg O. Factors affecting patient adherence to DOTS in urban Kathmandu. Nepal. Int J Tuberc Lung Dis. 2006;10(3):270–6.PubMed
19.
go back to reference Chang KC, Leung CC, Tam CM. Risk factors for defaulting from anti-tuberculosis treatment under directly observed treatment in Hong Kong. Int J Tuberc Lung Dis. 2004;8(12):1492–8.PubMed Chang KC, Leung CC, Tam CM. Risk factors for defaulting from anti-tuberculosis treatment under directly observed treatment in Hong Kong. Int J Tuberc Lung Dis. 2004;8(12):1492–8.PubMed
Metadata
Title
The value of initial cavitation to predict re-treatment with pulmonary tuberculosis
Authors
Qiusheng Huang
Yongmei Yin
Shougang Kuai
Yan Yan
Jun Liu
YingYing Zhang
Zhongbao Shan
Lan Gu
Hao Pei
Jun Wang
Publication date
01-12-2016
Publisher
BioMed Central
Published in
European Journal of Medical Research / Issue 1/2016
Electronic ISSN: 2047-783X
DOI
https://doi.org/10.1186/s40001-016-0214-0

Other articles of this Issue 1/2016

European Journal of Medical Research 1/2016 Go to the issue